Immunotherapy Treatment Strategies for Low-Grade Serous Ovarian Cancer

Video

Robert Coleman, MD, FACOG, FACS, reviews data from a study investigating combination letrozole plus ribociclib in patients with low-grade serous ovarian cancer.

CN_RO360_EC_SGO_Seg09_GOG3026
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
      Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
      ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
      ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
      Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
      Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
      Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
      Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
      Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
      Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer
      The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
      Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer
      Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
      Distinguishing Low-Grade Serous Ovarian Cancer From Other Ovarian Cancer Types
      Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
      Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
      Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
      Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
      Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
      Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
      Related Content
      The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

      Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

      Roman Fabbricatore
      April 2nd 2025
      Article

      The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

      Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

      Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

      Kathleen N. Moore, MD, MS
      March 17th 2025
      Podcast

      Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

      Social Determinants of Health Negatively Affected Endometrial Cancer Diagnosis

      Social Determinants of Health Negatively Affected Endometrial Cancer Diagnosis

      Tim Cortese
      March 19th 2025
      Article

      Factors such as language spoken, social vulnerability index characteristics, and insurance type were found to alter endometrial cancer diagnoses and led to worse outcomes.

      Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

      Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

      John Paul Diaz, MD
      November 4th 2024
      Podcast

      Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

      Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

      Vulvar Cancer Survival Discrepancies Seen in Year 1 of COVID-19 Pandemic

      Roman Fabbricatore
      March 19th 2025
      Article

      Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

      Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

      Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

      Ariana Pelosci
      March 18th 2025
      Article

      Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.